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background: Results of randomized clinical trials (RCT) demonstrate that novel oral anticoagulants (NOAC) are effective therapies for preventing 
stroke in non-valvular atrial fibrillation (NVAF).
objEctiVE: To estimate the change in medical costs associated with each NOAC (apixaban, dabigatran, and rivoraxaban) instead of warfarin in a 
real world, NVAF population.
methods: Patients with NVAF during 2007-2010 were selected from a Medco population of U.S. health plans. Stroke and major bleeding excluding 
intracranial hemorrhage (MBEIH) events were identified using diagnosis codes on medical claims. Real-world (RW) reference event rates were 
calculated during periods of warfarin exposure. RW event rates for NOACs were estimated by multiplying the corresponding relative risk (RR) from 
the RCTs by each reference rate. Absolute risk reductions (ARR) or the number of events avoided were then estimated. Changes in medical costs 
associated with each NOAC were calculated by applying the ARR to the one-year incremental cost for each event.
results: Results are summarized in TABLE. Compared to RW warfarin, use of apixaban and dabigatran resulted in total (stroke plus MBEIH) medical 
cost reductions of $1,245 and $555 respectively during a patient year (PY). Rivaroxaban resulted in a medical cost increase of $144.
TABLE:
RW Event Rate per 
100 PYs Warfarin 
Exposure
Apixaban vs. Warfarin Dabigatran vs. Warfarin Rivaroxaban vs. Warfarin
Number of Events 
Avoided/ 1 PY with 
NOAC*
Change in 
Medical 
Costs/ PY**
Number of Events 
Avoided/1 PY with 
NOAC*
Change in 
Medical 
Costs/ PY**
Number of Events 
Avoided/1 PY with 
NOAC*
Change in 
Medical Costs/ 
PY**
Stroke 5.3 -0.011 -$493 -0.018 -$806 -0.008 -$358
MBEIH 10.0 -0.021 -$752 +0.007 +$251 +0.014 +$502
*Positive values indicate an increase in events with NOAC vs. warfarin,**Positive values indicate an increase in costs with NOAC vs. warfarin, PY = 
person years
conclusions: If RRRs demonstrated in RCTs persist in RW, apixaban would confer the greatest medical cost savings vs. warfarin, resulting from 
significantly lower rates of both stroke and MBEIH.
